Next-Generation Self-Administered Drug-Device Combinations
New Technologies and Business Opportunities
Drug-device combination products are emerging as a novel delivery mechanism for
biologics and new classes of pharmaceuticals. The biologics market is poised for future
growth due to an aging global population, increasing incidence of chronic indications,
and a growing number of biologic products in late-stage clinical development. Current
biologic therapies are delivered by injection using traditional needle and syringes,
which require administration by a healthcare professional, have a high risk of
needlestick injury, and are painful to the patient. As the pharmaceutical industry
moves towards more patient-friendly therapies, self-administered drug-device combination
products are being investigated as a novel alternative to traditional injection devices
for the delivery of biologics.
Technology Catalysts International has developed a report that analyzes the current
technology and market potential for next-generation self-administered drug-device
combinations. This report features an overview of drug-device combination products
with a focus on self-injection devices (e.g., autoinjectors, pen injectors, and
prefilled syringes), active transdermal devices (e.g., microneedles), and inhalers.
The report also provides insight into regulatory challenges for drug-device combination
products in the US, EU, and Japan. Additionally, over 70 drug-device combination
technologies available for license are profiled. This report should be of strong
value to pharma companies developing biopharmaceutical products and innovative
delivery devices to help them differentiate their products or generic companies
developing biosimilars and biobetters.
Key information presented in the report includes:
- Product and Technology Introduction
- Overview of drug-device combination products
- Advantages and challenges with different drug-device combinations
- Analysis of therapeutic trends
- Market Landscape Analysis of Drug-Device Combinations
- Sales of leading drug-device combination products in 2011
- Pipeline products and market forecasts
- Regulatory Requirements for Drug-Device Combinations
- Recent published guidance
- Allergy
- Technology Licensing Opportunities
- Detailed profiles of drug-device combination technologies
- Updated contact information to initiate licensing agreements
